S434
Clinical - Gynaecological
ESTRO 2026
months (9.1 - 28.2). Subsequent median PFS was: PFS 1 10.8(6.4 - 17.4), PFS2: 6.3(4.3 – 11.9), PFS3: 8.0(4.4 - 12.6), PFS4: 7.9(4.7 - 12.6), PFS5: 5.2(3.8 – 7.2) months. Median (IQR) PPS following first progression for all patients was 30.2(16.3 - 53.5) months, and 33.4(18.5 - 51.4) months for those treated with re-irradiation (Figure 1). PPS by clinical setting was 30.2(18.7 – 53.8) months for Class A (synchronous oligometastatic), 27.6(15.2- 61.6) months for Class B (metachronous oligometastatic), and 32.0(16.5-51.1) months for Class C (oligo- recurrent).
Conclusion: This multicentre analysis highlights that patients with oligometastatic or oligo- recurrent cervical cancer can experience prolonged survival beyond first progression through repeated local and systemic treatments. Re-irradiation appears to be associated with improved outcomes after progression. Keywords: Oligorecurrent, Oligometastatic, Cervix Cancer
Mini-Oral 1819 Prospective Observational Study
Comparing Late Adverse Events and Survival Outcomes in HIV Positive and Negative Cervical Cancer Patients in India Prachi Mittal 1 , Lavanya Gurram 1 , Sujan Kumar Ghosh 1 , Supriya Chopra 2 , Poonam Gera 3 , Sheela Sawant 4 , Saritha Pullan 1 , Ankita Gupta 2 , Prachi Sawant 1 , Jaya Ghosh 5 , Erle Robertson 6 , Hao Shen 6 , Umesh
Made with FlippingBook - Share PDF online